Golden Years?
Executive Summary
Strategic change in Europe's family owned pharmaceutical comapnies--be it consolidation, increased R&D, or internationalization--may be imminent since the standard bearers of tradition, the patriarchs of these family-owned firms, are reaching well beyond retirement age (generally 60 years old in continental Europe).